In cell encapsulation, transplanted cells are protected from immune rejection by an artificial, semipermeable membrane, potentially allowing transplantation (allo- or xenotransplantation) without the need for immunosuppression. Yet, despite some promising results in animal studies, the field has not lived up to expectations, and clinical products based on encapsulated cell technology continue to elude the scientific community. This commentary discusses the reasons for this, summarizes recent progress in the field and outlines what is needed to bring this technology closer to clinical application.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Stem cell microencapsulation maintains stemness in inflammatory microenvironment
International Journal of Oral Science Open Access 10 October 2022
-
Evaluation of Microfluidic Approaches to Encapsulate Cells into PEGDA Microparticles
Regenerative Engineering and Translational Medicine Open Access 28 September 2021
-
Advanced Biotechnology for Cell Cryopreservation
Transactions of Tianjin University Open Access 28 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chang, T.M.S. Semipermeable microcapsules. Science 146, 524–525 (1964).
Lim, F. & Sun, A.M. Microencapsulated islets as bioartificial endocrine pancreas. Science 210, 908–909 (1980).
Sun, Y.L., Ma, X.J., Zhou, D.B., Vacek, I. & Sun, A.M. Normalization of diabetes in spontaneously diabetic cynomologous monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J. Clin. Invest. 98, 1417–1422 (1996).
Hortelano, G., Al-Hendy, A., Ofosu, F.A. & Chang, P.L. Delivery of human Factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 87, 5095–5103 (1996).
Xu, W., Liu, L. & Charles, I.G. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J. 16, 213–215 (2002).
Prakash, S. & Chang, T.M.S. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Med. 2, 883–887 (1996).
Soon-Shiong, P. et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 343, 950–951 (1994).
Hasse, C., Klock, G., Schlosser, A., Zimmermann, U. & Rothmund, M., Parathyroid allotransplantation without immunosuppression. Lancet 351, 1296–1297 (1997).
Lanza, R.P., Hayes, J.L. & Chick, W.L. Encapsulated cell technology. Nature Biotechnol. 14, 1107–1111 (1996).
Shapiro, A.M.J. et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230–238 (2000).
Hunkeler, D. et al. Objectively assessing bioartificial organs. Ann. NY Acad. Sci. 944, 456–471 (2001).
Anilkumar, A.V., Lacik, I. & Wang, T.G. A novel reactor for making uniform capsules. Biotechnol. Bioeng. 75, 581–589 (2001).
Strand, B.L. et al. Poly-l-lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant. 10, 263–275 (2001).
Calafiore, R. et al. Transplantation of minimal volume microcapsules in diabetic high mammalians. Ann. NY Acad. Sci. 875, 219–232 (1999).
Wang, T. et al. An encapsulation system for the immunoisolation of pancreatic islets. Nature Biotechnol. 15, 358–362 (1997).
De Vos, P. et al. Long-term biocompatibility, chemistry, and function of microencapsulated pancreatic islets. Biomaterials 24, 305–312 (2003).
Murphy, F.A. The public health risk of animal organ and tissue transplantation into humans. Science 273, 746–747 (1996).
Günzburg, W.H. & Salmons, B. Xenotransplantation: Is the risk of viral infection as great as we thought? Mol. Med. Today 6, 199–208 (2000).
Hunkeler, D. Allo transplants xeno: as bioartificial organs move to the clinic. Ann. NY Acad. Sci. 944, 1–6.
Bach, F.H. & Fineberg, H.V. Call for a moratorium on xenotransplants. Nature 391, 326 (1998).
Aebischer, P., Hottinger, A.F. & Déglon, N. Cellular xenotransplantation. Nature Med. 5, 852 (1999).
Hunkeler, D. et al. Bioartificial organs and acceptable risk. Nature Biotechnol. 17, 1045 (1999).
Calafiore, R. et al. Cellular support systems for alginate microcapsules containing islets as composite bioartificial pancreas. Ann. NY Acad. Sci. 944, 240–251 (2001).
De Vos, P., Hamel, A.F. & Tatarkiewicz, K. Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia 45, 159–173 (2002).
De Vos, P. & Marchetti, P. Encapsulation of pancreatic islets for transplantation in diabetes: the untouchable islets. Trends Mol. Med. 8, 363–366 (2002).
US Pharmacopeia and National Formulary (Rockville, Maryland). 1046, 2762–2790 (2002).
Check, E. Diabetes trial stirs debate on safety of xenotransplants. Nature 419, 5 (2002).
Mares-Guia, M. & Ricordi, C. Hetero-polysaccharide conjugate and methods of making and using the same. US Patent 6,281,341 (2001).
King, A. et al. Improvement of the biocompatibility of alginate/poly-l-lysine/alginate microcapsules by the use of epimerised alginate as a coating. J. Biomed. Mat. Res. (in press).
Desai, T.A. Microfabrication technology for pancreatic cell encapsulation. Exp. Opin. Biol. Ther. 2, 633–646 (2002).
Pelegrin, M. et al. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther. 5, 828–834 (1998).
Löhr, M. et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357, 1591–1592 (2001).
Read, T.A. et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nature Biotechnol. 19, 29–34 (2001).
Joki, T. et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nature Biotechnol. 19, 35–39 (2001).
Cirone, P., Bourgeois, J.M., Austin, R.C. & Chang, P.L. A novel approach to tumor suppression with microencapsulated recombinant cells. Hum. Gene Ther. 13, 1157–1166 (2002).
Drukker, M. et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc. Natl. Acad. Sci. USA 99, 9864–9869 (2002).
Dove, A. Cell-based therapies go live. Nature Biotechnol. 20, 339–343 (2002).
Orive, G., Hernández, R.M., Gascón, A.R., Igartua, M. & Pedraz, J.L. Encapsulated cell technology: from research to market. Trends Biotechnol. 20, 382–387 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Orive, G., Hernández, R., Gascón, A. et al. Cell encapsulation: Promise and progress. Nat Med 9, 104–107 (2003). https://doi.org/10.1038/nm0103-104
Issue Date:
DOI: https://doi.org/10.1038/nm0103-104
This article is cited by
-
A Novel Rat Model of Embolic Cerebral Ischemia Using a Cell-Implantable Radiopaque Hydrogel Microfiber
Translational Stroke Research (2023)
-
Stem cell microencapsulation maintains stemness in inflammatory microenvironment
International Journal of Oral Science (2022)
-
Injectable hydrogels for bone and cartilage tissue engineering: a review
Progress in Biomaterials (2022)
-
Evaluation of Microfluidic Approaches to Encapsulate Cells into PEGDA Microparticles
Regenerative Engineering and Translational Medicine (2022)
-
Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets
Nature Biomedical Engineering (2021)